{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hormone-receptor-positive+Breast+Cancer&page=14",
    "query": {
      "condition": "Hormone-receptor-positive Breast Cancer",
      "page": 14
    },
    "page_size": 10
  },
  "pagination": {
    "page": 14,
    "page_size": 10,
    "total_count": 411,
    "total_pages": 42,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hormone-receptor-positive+Breast+Cancer&page=15&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hormone-receptor-positive+Breast+Cancer&page=13&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T10:00:48.734Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00206414",
      "title": "Arimidex/Faslodex/Iressa Study: A Trial Using Arimidex, Faslodex and Iressa in Women With Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "BREAST CANCER"
      ],
      "interventions": [
        {
          "name": "Iressa Day 1 given with Arimidex and Faslodex",
          "type": "DRUG"
        },
        {
          "name": "Iressa Day 21 given with Arimidex and Faslodex",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Baylor Breast Care Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 15,
      "start_date": "2003-01",
      "completion_date": "2006-09",
      "has_results": false,
      "last_update_posted_date": "2013-02-05",
      "last_synced_at": "2026-10-14T10:00:48.734Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00206414"
    },
    {
      "nct_id": "NCT06517212",
      "title": "Tirzepatide Weight Loss for MRD+ Early Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Breast Neoplasms",
        "Breast Cancers"
      ],
      "interventions": [
        {
          "name": "Tirzepatide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Baylor Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2024-11-26",
      "completion_date": "2030-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-02-12",
      "last_synced_at": "2026-10-14T10:00:48.734Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06517212"
    },
    {
      "nct_id": "NCT02246621",
      "title": "A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Abemaciclib",
          "type": "DRUG"
        },
        {
          "name": "Anastrozole",
          "type": "DRUG"
        },
        {
          "name": "Letrozole",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 493,
      "start_date": "2014-11-06",
      "completion_date": "2026-12",
      "has_results": true,
      "last_update_posted_date": "2026-02-03",
      "last_synced_at": "2026-10-14T10:00:48.734Z",
      "location_count": 20,
      "location_summary": "Chandler, Arizona • Springdale, Arkansas • Bakersfield, California + 13 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02246621"
    },
    {
      "nct_id": "NCT04553133",
      "title": "PF-07104091 as a Single Agent and in Combination Therapy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Small Cell Lung Cancer",
        "Ovarian Cancer",
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "PF-07104091 monotherapy dose escalation",
          "type": "DRUG"
        },
        {
          "name": "PF-07104091 + palbociclib + fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "PF-07104091 + palbociclib + letrozole",
          "type": "DRUG"
        },
        {
          "name": "PF-07104091 monotherapy dose expansion (ovarian)",
          "type": "DRUG"
        },
        {
          "name": "PF-07104091 monotherapy dose expansion (SCLC)",
          "type": "DRUG"
        },
        {
          "name": "PF-07104091 + Fulvestrant (post CDK4/6)",
          "type": "DRUG"
        },
        {
          "name": "PF-0704091 + Fulvestrant (post CDK4/6)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 157,
      "start_date": "2020-09-16",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-06",
      "last_synced_at": "2026-10-14T10:00:48.734Z",
      "location_count": 17,
      "location_summary": "Clive, Iowa • Des Moines, Iowa • Louisville, Kentucky + 7 more",
      "locations": [
        {
          "city": "Clive",
          "state": "Iowa"
        },
        {
          "city": "Des Moines",
          "state": "Iowa"
        },
        {
          "city": "Des Moines",
          "state": "Iowa"
        },
        {
          "city": "Des Moines",
          "state": "Iowa"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04553133"
    },
    {
      "nct_id": "NCT03155997",
      "title": "Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Abemaciclib",
          "type": "DRUG"
        },
        {
          "name": "Standard Adjuvant Endocrine Therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5637,
      "start_date": "2017-07-12",
      "completion_date": "2029-05",
      "has_results": true,
      "last_update_posted_date": "2026-04-24",
      "last_synced_at": "2026-10-14T10:00:48.734Z",
      "location_count": 162,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Gilbert, Arizona + 104 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Goodyear",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03155997"
    },
    {
      "nct_id": "NCT07590583",
      "title": "Biology Guided Therapy Recommendations for Treatment Determination of Hormone Receptor-Positive Advanced, Unresectable or Metastatic Breast Cancer, ENDORSE Trial",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Hormone Receptor-Positive Breast Carcinoma",
        "Anatomic Stage III Breast Cancer AJCC v8",
        "Anatomic Stage IV Breast Cancer AJCC v8",
        "Metastatic Hormone Receptor-Positive Breast Carcinoma",
        "Unresectable Hormone Receptor-Positive Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Electronic Health Record Review",
          "type": "OTHER"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Treatment Planning",
          "type": "OTHER"
        },
        {
          "name": "Treatment Regimen",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2026-12-19",
      "completion_date": "2027-12-02",
      "has_results": false,
      "last_update_posted_date": "2026-05-15",
      "last_synced_at": "2026-10-14T10:00:48.734Z",
      "location_count": 2,
      "location_summary": "Duarte, California • Irvine, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07590583"
    },
    {
      "nct_id": "NCT00267553",
      "title": "Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Neoplasms",
        "Neoplasms, Hormone-Dependent"
      ],
      "interventions": [
        {
          "name": "Atamestane",
          "type": "DRUG"
        },
        {
          "name": "toremifene",
          "type": "DRUG"
        },
        {
          "name": "letrozole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Intarcia Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 200,
      "start_date": "2005-11",
      "completion_date": "2006-06",
      "has_results": false,
      "last_update_posted_date": "2007-09-10",
      "last_synced_at": "2026-10-14T10:00:48.734Z",
      "location_count": 6,
      "location_summary": "Greenbrae, California • Saint Joseph, Michigan • Kansas City, Missouri + 3 more",
      "locations": [
        {
          "city": "Greenbrae",
          "state": "California"
        },
        {
          "city": "Saint Joseph",
          "state": "Michigan"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Norfolk",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00267553"
    },
    {
      "nct_id": "NCT00615524",
      "title": "Phase II Study Evaluating Exemestane Alone Or In Combination With Pazopanib In Postmenopausal Women With Hormone Receptor Positive Breast Cancer",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hormone-receptor Positive Breast Cancer"
      ],
      "interventions": [
        {
          "name": "exemestane and pazopanib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 0,
      "start_date": "2008-04",
      "completion_date": "2012-11",
      "has_results": false,
      "last_update_posted_date": "2018-01-12",
      "last_synced_at": "2026-10-14T10:00:48.734Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00615524"
    },
    {
      "nct_id": "NCT06374459",
      "title": "Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Zumsemetinib",
          "type": "DRUG"
        },
        {
          "name": "Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "Zoledronic acid",
          "type": "DRUG"
        },
        {
          "name": "Denosumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 152,
      "start_date": "2025-01-30",
      "completion_date": "2032-05-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-13",
      "last_synced_at": "2026-10-14T10:00:48.734Z",
      "location_count": 3,
      "location_summary": "Westwood, Kansas • Rochester, Minnesota • St Louis, Missouri",
      "locations": [
        {
          "city": "Westwood",
          "state": "Kansas"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06374459"
    },
    {
      "nct_id": "NCT04906395",
      "title": "Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "TOL2506",
          "type": "DRUG"
        },
        {
          "name": "Tamoxifen",
          "type": "DRUG"
        },
        {
          "name": "Letrozole Tablets",
          "type": "DRUG"
        },
        {
          "name": "Anastrozole Tablets",
          "type": "DRUG"
        },
        {
          "name": "Exemestane Tablets",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tolmar Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 250,
      "start_date": "2021-07-01",
      "completion_date": "2026-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-29",
      "last_synced_at": "2026-10-14T10:00:48.734Z",
      "location_count": 17,
      "location_summary": "Greenbrae, California • Parker, Colorado • Chicago, Illinois + 14 more",
      "locations": [
        {
          "city": "Greenbrae",
          "state": "California"
        },
        {
          "city": "Parker",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Glenn Dale",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04906395"
    }
  ]
}